Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.38) by 35.64 percent. This is a 5.56 percent increase over losses of $(0.54) per share from the same period last year.